Patent · US Active

Multi-epitope fusion protein of an HCV antigen and uses thereof

US11078241B2 · kind B2 · utility

0Cited by

0References

13Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Barbara Upmeier · Iffeldorf, DE
Ralf Bollhagen · Penzberg, DE
Toralf Zarnt · Penzberg, DE

Key dates

Filing date	Jan 24, 2020
Grant date	Aug 3, 2021
Priority date	—
Expiry date	Jan 24, 2040

Classification

Technology area (CPC G)Physics
CPC primaryG01N2496/00
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The disclosure relates to a multi-epitope fusion protein as well as to its use as calibrator and/or control in an in vitro diagnostics immunoassay for detecting HCV core antigen. The multi-epitope fusion protein has two to six different non-overlapping linear peptides present in the amino acid sequence of hepatitis C virus (HCV) core protein, wherein each of the peptides is separated from the other peptides by a spacer consisting of a non-HCV amino acid sequence and having a chaperone amino acid sequence. No further HCV specific amino acid sequences are present in the polypeptide. A further aspect relates to a reagent kit for detecting HCV core antigen containing said multi-epitope fusion protein as calibrator or control or both.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.